CN112543637A - 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途 - Google Patents
伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途 Download PDFInfo
- Publication number
- CN112543637A CN112543637A CN201980050262.XA CN201980050262A CN112543637A CN 112543637 A CN112543637 A CN 112543637A CN 201980050262 A CN201980050262 A CN 201980050262A CN 112543637 A CN112543637 A CN 112543637A
- Authority
- CN
- China
- Prior art keywords
- seq
- irinotecan
- antibody
- tumor
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本申请提供了伊立替康联合免疫检查点抑制剂和5‑FU在制备预防或治疗肿瘤疾病的药物中的用途。具体而言，本申请提供了伊立替康或其可药用盐联合PD‑L1抗体或抗原结合片段和5‑FU在制备预防或治疗肿瘤疾病的药物中的用途。
Description
PCT国内申请，说明书已公开。
Claims (19)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018112484780 | 2018-10-25 | ||
| CN201811248478 | 2018-10-25 | ||
| PCT/CN2019/113009 WO2020083338A1 (zh) | 2018-10-25 | 2019-10-24 | 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112543637A true CN112543637A (zh) | 2021-03-23 |
| CN112543637B CN112543637B (zh) | 2023-04-04 |
Family
ID=70330288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980050262.XA Active CN112543637B (zh) | 2018-10-25 | 2019-10-24 | 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途 |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN112543637B (zh) |
| TW (1) | TW202029964A (zh) |
| WO (1) | WO2020083338A1 (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107614529A (zh) * | 2015-11-17 | 2018-01-19 | 苏州盛迪亚生物医药有限公司 | Pd‑l1抗体、其抗原结合片段及其医药用途 |
-
2019
- 2019-10-24 WO PCT/CN2019/113009 patent/WO2020083338A1/zh active Application Filing
- 2019-10-24 CN CN201980050262.XA patent/CN112543637B/zh active Active
- 2019-10-24 TW TW108138422A patent/TW202029964A/zh unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107614529A (zh) * | 2015-11-17 | 2018-01-19 | 苏州盛迪亚生物医药有限公司 | Pd‑l1抗体、其抗原结合片段及其医药用途 |
Non-Patent Citations (4)
| Title |
|---|
| FUMET J-D, ET AL.: "《Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer》", 《EMSO OPEN》 * |
| GLEN JW: "《A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy》", 《PLOS ONE》 * |
| MASATO T ET AL.: "《Down-regulation of PD-1 ligands by chemotherapeutic agents via inhibition of STAT3 activity enhances T cell-stimulating ability of dendritic cell》", 《CANCER RESEARCH》 * |
| STEFANIA O ET AL.: "《Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma》", 《BJC》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020083338A1 (zh) | 2020-04-30 |
| CN112543637B (zh) | 2023-04-04 |
| TW202029964A (zh) | 2020-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| US20210369748A1 (en) | Combination therapy for cancer treatment | |
| CN109963592B (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2020527332A5 (zh) | ||
| CN113613674A (zh) | 治疗小细胞肺癌的联用药物组合物 | |
| CN110785184A (zh) | 用于治疗癌症的方法，组合物和试剂盒 | |
| KR20220157515A (ko) | Liv1-adc와 화학요법제를 사용한 병용 요법 | |
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
| CN112543637B (zh) | 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途 | |
| TW202214287A (zh) | TGF-β受體的融合蛋白與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途 | |
| WO2021063331A1 (zh) | EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途 | |
| CN111065412B (zh) | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 | |
| CN113491769A (zh) | 药物联合 | |
| CN110013552B (zh) | 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途 | |
| AU2020228385A1 (en) | Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors | |
| CN111093703A (zh) | 免疫治疗剂、核苷类抗代谢物和铂类联合在制备治疗肿瘤的药物中的用途 | |
| CN111035759A (zh) | 阿帕替尼与抗pd-1抗体联合在制备治疗软组织肉瘤的药物中的用途 | |
| CN112439060B (zh) | Pd-l1免疫疗法的新用途 | |
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| CN115944741A (zh) | 含TGF-β受体的融合蛋白与紫杉类、核苷类似物联合在制备治疗胰腺癌药物中的用途 | |
| EP3896089A1 (en) | Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases | |
| CN117427186A (zh) | 抗her2抗体药物偶联物联合抗pd-l1抗体在制备治疗肺癌的药物中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |